Big Pharmaceuticals and Their Underhanded Methods

Former pharmaceutical executive Dr. John Virapen, who revealed the underhanded methods used by big pharma to get drugs approved and to rake in massive profits.

Speaking from his personal experience, Virapen recounted the chicanery he witnessed, and participated in, when he was an executive in Sweden with the drug company Eli Lilly.

He explained that they wanted to introduce the drug Prozac to Sweden, because it is a “prestige country” and approval there would help spread the drug to other countries. Virapen alleged that he gave a $30,000 bribe, along with promises of future payoffs, to a Swedish official to expedite the approval process, which normally can take between one and nine years. However, when Eli Lilly balked at giving a 5 milligram sample of the drug to Swedish officials for testing, they denied the approval of Prozac and Virapen was subsequently fired for failing to get the drug approved.

Following his departure from Eli Lilly, Virapen hoped to work with other pharmaceutical companies but was dismayed to learn that his experience was not an isolated incident. He declared that the drug companies “don’t care, whatsoever, for people’s health” and are only focused on making money for their shareholders.

To bolster his argument, he cited the massive amounts of money that have allegedly gone towards drug research and claimed that, in the last 50 years, no medicine has truly been developed to cure any actual diseases. On where that money really goes, he theorized that it gets funneled to politicians, universities, and insurance companies in order to consolidate more power for big pharma.

He lamented that the vast amount of money yielded by what he called the “pharmaceutical industrial complex” has resulted in the field being virtually impervious to true oversight. As an example of this power, Virapen cited the fines that have been levied against pharmaceutical companies for illegal marketing, a dangerous practice that can result in the death of misprescribed patients.

According to him, the profits from the sale of those drugs far outweigh the imposed penalties. Therefore, the pharmaceutical companies will pay the fines so that then they can keep selling medicine, rather than take the battle to court and risk having the sale of the drug halted while the case is pending.

Biography:

Dr. John Virapen worked more than 35 years in the pharmaceutical industry. In Sweden he was general manager of Eli Lilly & Company and was involved in the market launch of several drugs. His first book was about his activity as a manager in the pharmaceutical industry in 2006 under the pseudonym “John Rengen.”

Dr. Virapen is now dedicated to expose and create awareness on how the pharmaceutical industry is operating with their own best interest as their primary goal.

 

Print Friendly, PDF & Email

Leave a Reply

Your email address will not be published. Required fields are marked *